Since no reports associate the development of hepatic steatosis with a decrease in calpain activity and CAPN1 protein abundance, we performed a prove of concept experiment in the human hepatocarcinoma cell line model (HepG2). The gene discussed is CAPN1; the disease is fatty liver disease.